WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules

This development further expands the company’s Finished Dosage Form (FDF) portfolio and reflects its focus on reliable, responsible, and sustainable partnership models across the pharmaceutical value chain. WELDING PHARMA FDF supports partners with value-oriented solutions ranging from development and market access support to long term supply concepts.

“With this milestone, we continue to strengthen our role as a reliable partner for the pharmaceutical industry,” said Lars Hallmayer, Managing Director, WELDING GmbH & Co. KG. “Our approach combines regulatory expertise, transparent collaboration, and a long-term commitment to responsible business practices.”

The company views this authorization as part of its broader strategy to create sustainable economic value through trusted partnerships and international market expertise. With decades of experience in the pharmaceutical sector and a strong global network, WELDING PHARMA FDF works closely with partners to develop and implement tailored product and licensing solutions.

Further steps toward market availability will be taken in accordance with applicable national requirements.

For media inquiries, please contact:
https://welding.eu/…